The FDA approved cabozantinib (Cabometyx, Exelixis) for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed after vascular endothelial growth factor (VEGFR)-targeted therapy and who are ineligible or refractory to radioactive iodine.
Efficacy was evaluated in the randomized, double-blind, placebo-controlled, multicenter COSMIC-311trial (ClinicalTrials.gov Identifier: NCT03690388). In the trial,